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Article Information  ABSTRACT 
Received: 12th November 2019  Atovaquone and Mefloquine hydrochloride are well known anti-malarial drugs. Literature 
survey reveals that there was no method available for the selected drug combination. In this way, 
here an endeavour has been made to develop simple, precise, fast method for simultaneous 
estimation of atovaquone and mefloquine hydrochloride in bulk drug by using RP-HPLC 
method. The method was carried out by using gradient HPLC on C18 column using Shimadzu 
prominence LC 20 AD and mobile phase comprised of Methanol:ACN:Water in the ratio of 
85:7.5:7.5 (pH 2.9 was adjusted with OPA). The method was performed with 10µl injection 
volume. The UV detection was done at 231nm.The retention times of atovaquone and 
mefloquine hydrochloride were 7.6 and 2.6 min respectively.  The proposed method was 
validated according to ICH guidelines. The validation parameters were linearity, accuracy, 
precision (inter-day, intra-day and repeatability) and robustness etc. Linearity was in the range 
of 80-120µg/ml for atovaquone and 40-60µg/ml for mefloquine hydrochloride. The percent 
recoveries of both drugs were 99.99-100% and 92.05-99.09%. This method is suitable for the 
routine analysis of atovaquone and mefloquine hydrochloride in bulk drugs either individually 
or in mixture 
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INTRODUCTION 
Atovaquone and Mefloquine hydrochloride (Figure 1) are broad 
spectrum anti-parasitic drugs used in the treatment of malaria [1-
4]. Atovaquone is a hydroxy napthaquinone or an analogue of 
ubiquinone which is highly lipophilic in nature and used for 
treatment and prevention of chloroquine–resistant P. falciparum 
in combination with proguanil [5-6]. Atovaquone plays a wide 
important role in disease management of malaria because of 
drug resistance, intolerable side effects of other existing anti-
malarials [7-8]. Atovaquone is a competitive inhibitor of 
ubiquinol. It inhibits mitochondrial electron transport chain at 
the bc1 complex that leads to loss of mitochondrial function. 
During intra-erythrocytic phase of infection, a key job of the 
parasite in mitochondria is to give orotate for pyrimidine through 
the action of dihydro-orotate dehydrogenase (DHODH). 
Inhibition of bc1 complex by atovaquone impacts on the 
concentration of metabolites in the pyrimidine biosynthesis 
pathway [9-16]. 
Mefloquine hydrochloride is a phospholipid-interacting anti-
malarial drug. It is very effective against Plasmodium 
falciparum with very few side effects [5-6][17-19].Basically 
Mefloquine is a quinoline-methanol derivative with antimalarial, 
anti-inflammatory and potential chemosensitization and 
radiosensitization activities [20-21]. 
 
 
 
 
 
 
(a)     (b) 
Figure 1. Structure of (a) Atovaquone (b) Mefloquine 
hydrochloride 
 
MATERIALS AND METHOD 
The drugs atovaquone and mefloquine hydrochloride were 
purchased from Sanjay Biologicals Amritsar, Punjab India. All 
the solvents were of HPLC grade and purchased through S.D. 
fine-chem. Ltd., India. 
 
Instrumentation and chromatographic conditions 
The lambda max and iso-absorptive point were determined by 
using double beam UV-spectrophotometer, Lab India with UV 
win software. Method development and validation studies were 
carried out by using Shimadzu prominence LC 20 AD. Lab 
solution software used for instrument control. Column used for 
LC separation was Shimadzu octadecylsilane Hypersil (ODS) 
C18 having length of 150 ×4.6 mm, with particle size of 5 µ was 
used for the chromatographic separation of drugs. Injection 
volume was 10 µl and mobile phase composed of 
Methanol:ACN:Water in the ratio 85:7.5:7.5 (pH 2.9 was 
adjusted with OPA). The wavelength of detection was at 231 nm 
and run time was 15 minutes. 
 
Selection of wavelength  
The sensitivity of HPLC technique that utilizes UV detection 
relies upon appropriate selection of detection wavelength. For 
the selection of wavelength 50 µg/ml concentration of 
Atovaquone and 50 µg/ml of Mefloquine Hydrochloride used 
and overlain spectrum is taken. Atovaquone and Mefloquine 
hydrochloride was prepared. The solvent ratio was 50:50 v/v of 
water and methanol.  Iso-absorptive point was obtained at 231 
nm. The overlain spectrum of drugs was showed in figure 2. 
 
Figure 2.  Overlain spectrum of Atovaquone and Mefloquine 
hydrochloride. 
 
Analytical Method Validation 
The method was validated as per ICH guidelines. The 
parameters studied were linearity, accuracy, precision (intraday 
and interday precision and repeatability) and robustness [22]. 
 
Preparation of standard solution 
Atovaquone standard solution 
Standard Atovaquone (50 mg) was weighed and transferred to 
100 ml volumetric flask and dissolved with solvent 
(Methanol:ACN:Water pH 2.9 was adjusted with OPA). The 
contents were mixed and volume was made with solvent to 
obtain a solution containing 1000 µg/ml concentrations. From 
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the standard Atovaquone stock solution, volume of 0.8, 0.9, 1, 
1.1, 1.2 ml was pipetted out from 1000 µg/ml and transferred to 
volumetric flasks of 10 ml capacity. Then volume was made up 
to the mark with conc. of 80, 90, 100, 110, 120 µg/ml. 
 
Mefloquine hydrochloride standard stock solution 
Standard Mefloquine hydrochloride 50 mg was weighed and 
transferred to 100 ml volumetric flask and dissolved in solvent. 
The contents were mixed and volume was made with solvent to 
obtain a solution containing 1000 µg/ml concentrations.From 
the standard Mefloquine hydrochloride stock solution the 
volume of 0.4, 0.45, 0.5, 0.55, 0.6 ml was pipetted out from 1000 
µg/ml and transferred to volumetric flasks of 10 ml capacity. 
Then volume was made up to the mark with conc. of 40, 45, 50, 
55, 60 µg/ml. 
 
Linearity 
The linearity range for Atovaquone was 80-120 µg/ml and for 
Mefloquine hydrochloride was 40-60 µg/ml. The R2 value was 
calculated for both drugs. The linearity was plotted for peak area 
versus concentration. The injection was given at time interval of 
15 min with run time of 15 min.  
 
Accuracy 
The accuracy was done by performing recovery studies at 80, 
100 and 120% of test concentration of both the drugs. The 
samples were prepared in triplicate of Atovaquone (80,100,120 
µg/ml) and Mefloquine hydrochloride (40, 50, 60 µg/ml) and the 
accuracy was calculated by recovery studies. 
 
Precision 
In analytical method, precision is the degree of closeness of 
agreement between a series of measurements acquired from the 
different testing of a similar sample. Precision includes 
repeatability, inter and intraday precision and reproducibility. 
The repeatability was performed by six determinants of test 
concentration of each drug. The interday readings were taken as 
for intraday one. The SD and %RSD was calculated and 
evaluated. 
 
Robustness 
Robustness is a measure of its capacity to stay unaffected by 
little, but deliberate variations in method parameter. HPLC 
robustness was done by changing flow rate and wavelength 
respectively. 
RESULTS AND DISCUSSION 
Analytical Method Validation 
The validation parameters were summarized in table 8. The UV 
spectrum was obtained for both drugs at 200-400 nm scan as 
spectrum was mentioned in figure 2. The retention time for 
atovaquone was 7.6 and 2.6 and each chromatogram was 
mentioned in figure 3. The linearity of both drugs was found 
within the limits (R2≥0.992) and results were in figure 4 and 5 
and table 1 and 2.  
 
(a)
 
(b) 
 
(c) 
Figure 3. Chromatogram of (a) Atovaquone (b) Mefloquine 
hydrochloride (c) mixture of both drugs. 
 
The accuracy was done by performing recovery studies at 80, 
100 and 120% of test concentration of both the drugs. The 
samples were prepared in triplicate and the accuracy was 
calculated by recovery studies. The results of accuracy were 
mentioned in table 3 and 4 respectively. 
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Table 1. Results of linearity curve of Atovaquone at 
wavelength 231 nm. 
Sr. No Conc (µg/ml) Area (µ volt sec.) 
1 80 536965 
2 90 1381901 
3 100 2226410 
4 110 3248701 
5 120 3916799 
 
Figure 4. Linearity curve of Atovaquone at 231 nm. 
 
Table 2. Results of linearity curve of Mefloquine 
hydrochloride at wavelength 231 nm. 
Sr. No  Conc. (µg/ml)  Area (µ volt sec.)  
1 40 2444173 
2 45 2824901 
3 50 3057399 
4 55 3356069 
5 60 3636497 
 
Figure 5. Linearity curve of Mefloquine hydrochloride at 
231 nm. 
 
Table 3. % Drug Recovery of Atovaquone at wavelength 231 nm 
Recovery Sample Fortified Sample % 
Recovery Conc. (μg/ml) Peak Area Mean Peak Area Conc. (μg/ml) Peak Area Mean Peak Area 
80 
1381901 
1381895.5 80+100 
3608243 
3608244 99.98 
1381890 3608245 
100 
2226409 
2226410 100+100 
4452729 
4452733.5 100 
2226411 4452738 
120 
3248615 
3248658 120+100 
5475298 
5475294 99.99 
3248701 5475290 
 
Table 4. % Drug Recovery of Mefloquine Hydrochloride at wavelength 231 nm 
Recovery Sample Fortified Sample % Recovery 
Conc. (μg/ml) Peak Area Mean peak area Conc. (μg/ml) Peak area Mean peak area 
40 
2824901 
2824902 40+50 
5648704 
5648705 92.5 
2824903 5648706 
50 
3057399 
3057398.5 50+50 
6114726 
6114728.5 99.9 
3057398 6114719 
60 
3356069 
3356070 60+50 
6413571 
6413570 99.9 
3356071 6413569 
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Table 5(a). Intraday precision of Atovaquone and Mefloquine hydrochloride at 231 nm 
Drug Atovaquone Mefloquine hydrochloride 
Concentration 90 µg/ml 100 µg/ml 110 µg/ml 45 µg/ml 50 µg/ml 55 µg/ml 
Area 
1381901 
1381828 
1381892 
2226410 
2226398 
2226399 
3248701 
3248699 
3248723 
2824642 
2824901 
2824864 
3057666 
3057399 
3057962 
3354032 
3356070 
3356092 
Mean 1381874 2226402 3248708 2824802 3057676 3355398 
SD 39.804 6.658 13.315 140.07 281.62 1183.042 
%RSD 0.003 0.0003 0.0004 0.005 0.009 0.035 
 
Table 5(b). Interday Precision of Atovaquone 
Day Day 1 Day 2 Day 3 
Concentration 90 
µg/ml 
100 
µg/ml 
110 
 µg/ml 
90  
µg/ml 
100 
µg/ml 
110 
µg/ml 
90 
µg/ml 
100 
µg/ml 
110 µg/ml 
Area 
1381901 
1381828 
1381892 
2226410 
2226398 
2226399 
3248701 
3248699 
3248723 
1381828 
1381845 
1381816 
2226410 
2226424 
2226446 
3248699 
3248672 
3248685 
1381825 
1381849 
1381816 
2226438 
2226424 
2226452 
3248682 
3248655 
3248639 
Mean 1381874 2226402 3248708 1381830 2226427 3248685 1381830 2226438 3248659 
SD 39.804 6.658 13.315 14.57166 18.14754 13.5 17.058 14 21.733 
%RSD 0.003 0.0003 0.0004 0.001 0.008 0.004 0.001 0.0006 0.0006 
 
Table 5(c). Interday Precision of Mefloquine hydrochloride 
Day Day 1 Day 2 Day 3 
Concentration 45 µg/ml 50 µg/ml 55 µg/ml 45 µg/ml 50 µg/ml 55 µg/ml 45 µg/ml 50 µg/ml 55 µg/ml 
Area 
2824642 
2824901 
2824864 
3057666 
3057399 
3057962 
3354032 
3356070 
3356092 
2824642 
2824939 
2824811 
3057666 
3057381 
3057999 
3354232 
3356025 
3356186 
2824698 
2824939 
2824847 
3057623 
3057390 
3057999 
3354222 
3356025 
3356012 
Mean 2824802 3057676 3355398 2824797 3057682 3355481 2824828 3057671 3355420 
SD 140.07 281.62 1183.042 148.97 309.31 1084.6 121.61 307.2854 1037.23 
%RSD 0.005 0.009 0.035 0.005 0.01 0.03 0.004 0.01 0.03 
Table 6(a). Repeatability of atovaquone at 231 nm 
Sr. No Area (µ volt sec.) 
1 2226438 
2 2226424 
3 2226452 
4 2226422 
5 2226419 
6 2226474 
Mean 2226438 
SD 21.47 
%RSD 0.0009 
Table 6(b) Repeatability of mefloquine hydrochloride at 231 nm 
Sr. No  Area (µ volt sec.)  
1  3057623 
2  3057390 
3  3057999 
4  3057647 
5  3057332 
6  3057927 
Mean  3057653 
SD  271.27 
%RSD  0.008 
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Interday and intraday precision of concentration for Atovaquone 
90, 100, 110 µg/ml and Mefloquine hydrochloride 45, 50, 55 
µg/ml was prepared and data was obtained. 3 replicates were 
prepared for 3 days. The results were shown in table 5(a), 5(b), 
5(c) for Atovaquone and Mefloquine hydrochloride. 
 
For repeatability minimum of 6 determinants were prepared of 
100 µg/ml for Atovaquone and 50 µg/ml for Mefloquine 
hydrochloride and the chromatograms were obtained. The 
results were shown in table 6(a) for Atovaquone and table 6(b) 
for Mefloquine hydrochloride. 
 
Robustness results were shown in table 7(a) for change in flow 
rate and table 7(b) for change in mobile phase. 
 
Change in flow rate of mobile phase   
Table 7(a). Robustness of Atovaquone and Mefloquine 
hydrochloride at wavelength 231 nm by changing the flow rate. 
Flow rate 
(ml/min.) 
Difference Rt of 
Atovaquone 
(min.) 
Rt of Mefloquine 
hydrochloride 
(min.) 
0.9 -0.1 7.429 2.502 
1 0 7.520 2.656 
1.1 +0.1 7.565 2.606 
 
Change in Wavelength 
Table 7(b). Robustness of Atovaquone and Mefloquine 
hydrochloride at the wavelength 231±2 nm. 
Wavelength Difference 
Rt of 
Atovaquone 
(min.) 
Rt of Mefloquine 
hydrochloride 
(min.) 
229 -2 7.549 2.606 
231 0 7.546 2.605 
233 +2 7.548 2.602 
 
CONCLUSION 
The above developed RP-HPLC method for simultaneous 
estimation of Atovaquone and Mefloquine hydrochloride was 
simple, economic, precise, robust and accurate method. There 
were no HPLC method revealed till now on chosen combination 
of drugs. Subsequently, the developed method is great for the 
regular analysis and quality control of bulk drugs either 
individually or in combination. 
Table 8. Summary of validation parameters of RP-HPLC at 
231 nm wavelength. 
Parameter Atovaquone Mefloquine 
hydrochloride 
Linear range (µg/ml) 80-120 40-60 
Regression coefficient (R2) 0.997 0.995 
%Recovery 99.99 98.42 
Repeatability (n=6) %RSD 
NMT 2 
%RSD 
NMT 2 
Precision 
Interday precision 
Intraday precision 
 
%RSD 
NMT 2 
 
%RSD 
NMT 2 
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